Aceragen, Inc. (ACGN) vs BioCardia, Inc. (BCDA)
Aceragen, Inc. and BioCardia, Inc. are both Biotechnology companies. Aceragen, Inc. and BioCardia, Inc. are of similar size ($17.1M and $16.2M). Aceragen, Inc. grew revenue faster over the last twelve months: 1,226.3% against 0.71%. BioCardia, Inc. has the higher net margin (0.00% vs −467.5%) and the higher return on invested capital (0.00% vs −135.4%). Across the 17 metrics below, BioCardia, Inc. leads on 10 and Aceragen, Inc. on 7.
Valuation
Profitability
| Metric | ACGN | BCDA | Biotechnology median |
|---|---|---|---|
| Gross margin | 83.46% | 100.00% | 65.16% |
| Operating margin | (503.92%) | 0.00% | 0.00% |
| Net margin | (467.53%) | 0.00% | 0.00% |
| Free cash flow margin | (339.17%) | 0.00% | 0.00% |
| Return on equity | (169.66%) | (1,803.19%) | (57.72%) |
| Return on assets | (75.58%) | (214.47%) | (49.22%) |
| Return on invested capital | (135.35%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack